MS Speaks

Multiple Sclerosis => TREATMENTS => TYSABRI (natalizumab) => Topic started by: agate on June 08, 2019, 09:32:13 am

Title: (Abst.) Long-term disease activity and disability progression in RRMS patients on Tysabri
Post by: agate on June 08, 2019, 09:32:13 am

Not much information about just how the patients taking Tysabri (or other MS drugs) are doing over time but this research concludes:

Quote

When taking into account early inflammation and the impact of natalizumab on disease activity during the initial treatment phase, a higher than expected proportion of patients showed disability progression.

From PubMed, June 8, 2019--"Long-term disease activity and disability progression in RRMS patients on natalizumab" by researchers in Amsterdam, including two who are well known in MS research--Barkhof, Uitdehaag:


https://www.ncbi.nlm.nih.gov/pubmed/31174043